I stopped at Guitar Center in Nashville TN on the way to UWC and picked up an inexpensive Dean Markley soundboard transducer acoustic guitar pickup in case I wanted to run my KoAloha through my effects board. I ended up not using the effects or the transducer, and had almost forgotten I'd purchased it. It's the inexpensive "Artist Transducer" model and is intended for temporary use - attaches with sticky tack and has a long chord and plug instead of a jack. Placement is supposedly pretty critical on these things - at least on a guitar where moving them around can drastically change the response. I just stuck it right behind the bridge between the C and E strings. I was pleasantly surprised - the sound was pretty natural - I think maybe more natural than most USTs I've used. There was a little more noise than from most USTs, but not terrible. The sound was pretty open, I didn't feel like fooling with moving it around to optimize the response but I might on a day when I have more time.Īs near as I can tell the biggest drawbacks were more related to the temporary nature of the device than to the sound. That long chord is a real nuisance when you aren't using the pickup so you pretty much have to remove the pickup after every use. The sticky tack was pretty aggressive - it held better than I expected. The residue wouldn't rub off with a finger but did come off after rubbing with a bit of Renaissance wax. I think there might be a permanent, inside mount, soundboard transducer in my future. Dean Markly DM3001 Artist Acoustic Pick-up. Dean Markley's Artist pickup is a pickup which is so unique that it is patented. I liked the sound of this than I do USTs, and this was about the cheapest soundboard transducer out there. This is the most basic kind of piezo pick-up by Dean Markly. The microphone comes with a supply of special adhesive that gives you plenty of use, removing and replacing it over and again. These sorts of pick-ups are really popular for instruments like violins and cellos where you. The founding team has more than two decades of entrepreneurial experience.Housed in a maple wood housing, Artist Transducer gives you that sound that every professional artist wants. The Company uses its expertise in the development, manufacturing and regulatory approval process to develop oncology medications for treatment of cancer and prevention of cancer recurrence based on licensed technologies. Plug into Dean Markley's ProMag Plus XM Acoustical Pickup and see just how good your acoustic guitar can sound. For use with your own choice of any 1/4 inch cable or wireless device. Haskell Adler, Ph.D., MBA, senior licensing manager in Moffitt's Office of Innovation and Industry Alliances added, "I am impressed with the track record of the DeMelle team and look forward to their progress in bringing new therapeutics to market."ĭeMelle OncoPharma LLC is focused on developing pharmacological treatments for high-unmet need cancers, initially for pancreatic cancer. The ProMag Plus XM features a low-noise 24 inch cable terminating in a female 1/4 inch jack that connects to your guitar strap button. "Because new approaches to treating pancreatic cancer are badly needed, we are pleased to work with DeMelle to give patients more therapeutic options." Malafa, a surgical oncologist in the Department of Gastrointestinal Oncology at Moffitt. "With this agreement, DeMelle can build on the research done at Moffitt, and bring novel treatments to patients that have the potential to be safer and more effective," said Dr. DM3001 also demonstrated superior activity compared to standard of care, Gemcitabine. In animal studies, DM3001 inhibited pancreatic and colon cancer growth and metastasis through suppression of cancer stem cells by the NF-κB, STAT3, WNT and RAS/KRAS/MAPK/AKT pathways. In this study, DM3001 penetrated the pancreatic stromal barrier to produce regulated cell death in tumor cells with a minimal effect on normal tissue. In a Phase 1b clinical study of 25 pre-surgical pancreatic cancer patients, DM3001 demonstrated promising activity with minimal adverse events. "DeMelle plans to continue building on the significant scientific advancements achieved by Mokenge Malafa, M.D., and his colleagues at Moffitt, with the potential to bring novel treatments that modulates the novel Exportin-2 target," said George Bobotas, Ph.D., CEO of DeMelle OncoPharma. Based on the underlying biology, lead-product candidate DM3001 (Farnesyl-Di-Methyl-Chromanol) is also expected to treat and prevent a broad range of other cancers, currently under exploration. Under the terms of the agreement, DeMelle will utilize Moffitt's technology as a platform for developing innovative treatments against cancers expressing the novel Exportin-2 target. TARPON SPRINGS, FL / ACCESSWIRE / Ma/ DeMelle OncoPharma LLC ("DeMelle" or the "Company"), a clinical-stage biotechnology company, announced today an exclusive global licensing agreement with Moffitt Cancer Center to develop DM3001, a first-in-class targeted pancreatic cancer treatment. Company developing DM3001 as first-in-class treatment against novel cancer target
0 Comments
Leave a Reply. |